HomeCompareBXRX vs SPHD

BXRX vs SPHD: Dividend Comparison 2026

BXRX yields 9174.31% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXRX wins by $23597687873458488.00M in total portfolio value
10 years
BXRX
BXRX
● Live price
9174.31%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23597687873458488.00M
Annual income
$23,102,328,897,111,608,000,000.00
Full BXRX calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — BXRX vs SPHD

📍 BXRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXRXSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXRX + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BXRX pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXRX
Annual income on $10K today (after 15% tax)
$779,816.51/yr
After 10yr DRIP, annual income (after tax)
$19,636,979,562,544,865,000,000.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, BXRX beats the other by $19,636,979,562,544,865,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXRX + SPHD for your $10,000?

BXRX: 50%SPHD: 50%
100% SPHD50/50100% BXRX
Portfolio after 10yr
$11798843936729244.00M
Annual income
$11,551,164,448,555,804,000,000.00/yr
Blended yield
97.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BXRX right now

BXRX
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-15.9
Piotroski
1/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXRX buys
0
SPHD buys
0
No recent congressional trades found for BXRX or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXRXSPHD
Forward yield9174.31%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$23597687873458488.00M$26.5K
Annual income after 10y$23,102,328,897,111,608,000,000.00$571.32
Total dividends collected$23564675825677336.00M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BXRX vs SPHD ($10,000, DRIP)

YearBXRX PortfolioBXRX Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$928,131$917,431.19$11,133$432.85+$917.0KBXRX
2$80,572,213$79,579,112.81$12,363$450.36+$80.56MBXRX
3$6,542,624,325$6,456,412,056.54$13,695$467.39+$6542.61MBXRX
4$496,975,869,083$489,975,261,055.26$15,138$483.90+$496975.85MBXRX
5$35,315,297,301,597$34,783,533,121,678.35$16,697$499.88+$35315297.28MBXRX
6$2,347,816,625,029,715$2,310,029,256,917,006.50$18,382$515.31+$2347816625.01MBXRX
7$146,039,627,186,550,560$143,527,463,397,768,750.00$20,198$530.17+$146039627186.53MBXRX
8$8,499,944,982,314,035,000$8,343,682,581,224,426,000.00$22,157$544.46+$8499944982314.01MBXRX
9$462,952,314,342,881,700,000$453,857,373,211,805,700,000.00$24,266$558.18+$462952314342881.69MBXRX
10$23,597,687,873,458,490,000,000$23,102,328,897,111,608,000,000.00$26,536$571.32+$23597687873458488.00MBXRX

BXRX vs SPHD: Complete Analysis 2026

BXRXStock

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Full BXRX Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this BXRX vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXRX vs SCHDBXRX vs JEPIBXRX vs OBXRX vs KOBXRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.